SCOTTSDALE, AZ--(MARKET WIRE)--Sep 10, 2007 -- Health Enhancement Products, Inc. (OTC BB:HEPI.OB - News), a Scottsdale, Arizona company, announced today the publication of a peer-reviewed article describing results of a clinical trial involving its ProAlgaZyme product (PAZ). The trial was conducted by Dr. Julius Oben, Head of the Laboratory of Nutrition and Nutritional Biochemistry at the University of Yaounde, Cameroon.

The title, abstract and link to the article are reprinted below:

The effects of ProAlgaZyme novel algae infusion on metabolic syndrome and markers of cardiovascular health.

Background

Metabolic Syndrome, or Syndrome X, is characterized by a set of metabolic and lipid imbalances that greatly increases the risk of developing diabetes and cardiovascular disease. The syndrome is highly prevalent in the United States and worldwide, and treatments are in high demand. ProAlgaZyme, a novel and proprietary freshwater algae infusion in purified water, has been the subject of several animal studies and has demonstrated low toxicity even with chronic administration at elevated doses. The infusion has been used historically for the treatment of several inflammatory and immune disorders in humans and is considered well-tolerated. Here, the infusion is evaluated for its effects on the cardiovascular risk factors present in metabolic syndrome in a randomized double-blind placebo-controlled study involving 60 overweight and obese persons, ages 25-60. All participants received four daily oral doses (1 fl oz) of ProAlgaZyme (N=22) or water placebo (N=30) for a total of 10 weeks, and were encouraged to maintain their normal levels of physical activity. Blood sampling and anthropometric measurements were taken at the beginning of the study period and after 4, 8 and 10 weeks of treatment. Eight participants did not complete the study.

Results

ProAlgaZyme brought about statistically significant (p < 0.001) reductions in the following: weight, body fat, total cholesterol, LDL-cholesterol, triglycerides, C-reactive protein and fasting blood glucose levels, accompanied by a significant (p < 0.001) increase in HDL-cholesterol levels over the 10-week study period. The infusion was well-tolerated and no side effects were noted.

Conclusions

ProAlgaZyme (4 fl oz daily) consumption resulted in significant reductions in weight and blood glucose levels, while significantly improving serum lipid profiles and reducing markers of inflammation, thus improving cardiovascular risk factors in overweight and obese subjects over a course of 10 weeks with an absence of adverse side effects. Trial Registration: US ClinicalTrials.gov NCT00489333

Complete article can be viewed at http://www.lipidworld.com/content/6/1/20

About Health Enhancement Products, Inc. and ProAlgaZyme

Health Enhancement Products Inc. is a nutraceutical company engaged in the development of a Dietary Supplement product using only pure, all-natural ingredients. The company's sole product is ProAlgaZyme, a liquid product produced from algae grown in 100% distilled water. The liquid in which the algae are grown is drawn off, filtered, tested and bottled as ProAlgaZyme.

Except for any historical information, the matters discussed in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements involve risks and uncertainties. A number of factors could cause actual results to differ from those indicated in the forward-looking statements, including future clinical trial results being different than the company's results to date and the company's ability to fund its operations and market and sell its ProAlgaZyme product. Such statements are subject to a number of assumptions, risks and uncertainties. Readers are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in the forward-looking statements. The company undertakes no obligation to publicly update or revise forward-looking statements, whether as a result of new information or otherwise.

For more information, please visit www.heponline.com.